Drug-drug Interactions of Statins Potentially Leading to Muscle-Related Side Effects in Hospitalized Patients

1. WALLEY T, FOLINO-GALLO P, STEPHENS P, VAN GANSE E. Trends in prescribing utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005; 60:543-51.10.1111/j.1365-2125.2005.02478.xSearch in Google Scholar

2. KILDEMOES HW, STØVRING H, ANDERSEN M. Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. Br J Clin Pharmacol 2008; 66:885-95.10.1111/j.1365-2125.2008.03282.xSearch in Google Scholar

3. WALLEY T, FOLINO-GALLO P, SCHWABE U, VAN GANSE E. EUROMEDSTAT GROUP. Variations and increase in use of statins across Europe: data from administrative databases. BMJ 2004; 328:385-6.10.1136/bmj.328.7436.385Search in Google Scholar

4. TEELING M, BENNETT K, FEELY J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol 2005; 59:227-32.10.1111/j.1365-2125.2004.02256.xSearch in Google Scholar

5. DUBOIS RW, DEAN BB. Evolution of clinical practice guidelines: evidence supporting expanded use of medicines. Dis Manag 2006; 9:210-23.10.1089/dis.2006.9.210Search in Google Scholar

6. PETURSSON H1, GETZ L, SIGURDSSON JA, HETLEVIK I. Can individuals with a significant risk for cardiovascular disease be adequately identified by combination of several risk factors? Modelling study based on the Norwegian HUNT 2 population. J Eval Clin Pract 2009; 15:103-9.10.1111/j.1365-2753.2008.00962.xSearch in Google Scholar

7. BRUGTS JJ1, DECKERS JW. Statin prescription in men and women at cardiovascular risk: to whom and when? Curr Opin Cardiol 2010; 25:484-9.Search in Google Scholar

8. ARMITAGE J. The safety of statins in clinical practice. Lancet 2007; 370:1781-90.10.1016/S0140-6736(07)60716-8Search in Google Scholar

9. BRUCKERT E, HAYEM G, DEJAGER S, YAU C, BÉGAUD B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patient – -the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403-14.10.1007/s10557-005-5686-zSearch in Google Scholar

10. PASTERNAK RC, SMITH SC JR, BAIREY-MERZ CN, GRUNDY SM, CLEEMAN JI, LENFANT C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40:567-72.10.1016/S0735-1097(02)02030-2Search in Google Scholar

11. GRAHAM DJ, STAFFA JA, SHATIN D, ANDRADE SE, SCHECH SD, LA GRENADE L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292:2585-90.10.1001/jama.292.21.258515572716Search in Google Scholar

12. LAW M, RUDNICKA AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C-60C.10.1016/j.amjcard.2005.12.010Search in Google Scholar

13. JOY TR, HEGELE RA. Narrative review: statin-related myopathy. Ann Intern Med 2009; 150:858-68.10.7326/0003-4819-150-12-200906160-00009Search in Google Scholar

14. LÖFBERG M, JÄNKÄLÄ H, PAETAU A, HÄRKÖNEN M, SOMER H. Metabolic causes of recurrent rhabdomyolysis. Acta Neurol Scand 1998; 98:268-75.10.1111/j.1600-0404.1998.tb07307.xSearch in Google Scholar

15. ANTONS KA, WILLIAMS CD, BAKER SK, PHILLIPS PS. Clinical perspectives of statin induced rhabdomyolysis. Am J Med 2006; 119:400-409.10.1016/j.amjmed.2006.02.007Search in Google Scholar

16. JACOBSON TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008; 83:687-700.10.1016/S0025-6196(11)60897-5Search in Google Scholar

17. TAHA TA, DE MOOR CH, BARRETT DA, GERSHKOVICH P. Translational insight into statin-induced muscle toxicity: from cell-culture to clinical studies. Transl Res 2014; 164:85-109.10.1016/j.trsl.2014.01.01324530275Search in Google Scholar

18. CHATZIZISIS YS1, KOSKINAS KC, MISIRLI G, VAKLAVAS C, HATZITOLIOS A, GIANNOGLOU GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33:171-87.10.2165/11319380-000000000-0000020158283Search in Google Scholar

19. BAKHAI A, RIGNEY U, HOLLIS S, EMMAS C. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf 2012; 21:485-493.10.1002/pds.230822237927Search in Google Scholar

20. ITO MK, MAKI KC, BRINTON EA, COHEN JD, JACOBSON TA. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study. J Clin Lipidol 2014; 8:69-76.10.1016/j.jacl.2013.10.00624528687Search in Google Scholar

21. BALLANTYNE CM, CORSINI A, DAVIDSON MH, HOLDAAS H, JACOBSON TA, LEITERSDORF E, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163:553-64.10.1001/archinte.163.5.55312622602Search in Google Scholar

22. FERNANDEZ G, SPATZ E, JABLECKI C, PHILLIPS PS. Statin myopathy: a common dilemma not reflected in clinical trials. Clev Clin J Med 2011; 78:393-403.10.3949/ccjm.78a.10073Search in Google Scholar

23. Micromedex® 2.0, (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com/ (cited: March/31/2015).Search in Google Scholar

24. THE R DEVELOPMENT CORE TEAM. A language and environment for statistical computing. R Foundation for Statistical Computing; 2015. Available at http://www.R-project.org.Search in Google Scholar

25. DEVOLD HM, MOLDEN E, S SKURTVEIT, FURU K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. BR J Clin Pharmacol 2009; 2:234-41.10.1111/j.1365-2125.2008.03345.xSearch in Google Scholar

26. OMAR MA1, WILSON JP, COX TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35:1096-107.10.1345/aph.10228Search in Google Scholar

27. BOYD RA, STERN RH, STEWART BH, WU X, REYNER EL, ZEGARAC EA, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal p-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40:91-8.10.1177/00912700022008612Search in Google Scholar

28. BARRY M. Rosuvastatin-warfarin drug interaction. Lancet 2004; 363:328.10.1016/S0140-6736(03)15396-2Search in Google Scholar